Vanquish Bio
Biotechnology company developing cell-free biologic therapies derived from natural killer (NK) cell extracellular vesicles (EVs) for difficult-to-treat cancers. The organization conducts preclinical research and publishes experimental evidence of EV-mediated tumor penetration and selective cytotoxicity, is developing stable formulations for non-cryogenic storage and infusion delivery, and pursues AI/ML imaging partnerships to support early detection and targeted delivery. The company seeks collaborative partnerships for preclinical studies and planned clinical trials.
Industries
Nr. of Employees
small (1-50)
Products
Natural killer cell-derived extracellular vesicle therapeutic (preclinical candidate)
A cell-free biologic composed of extracellular vesicles derived from human natural killer cells designed to penetrate tumors and induce apoptosis in cancer cells; intended for intravenous infusion in clinical settings.
Natural killer cell-derived extracellular vesicle therapeutic (preclinical candidate)
A cell-free biologic composed of extracellular vesicles derived from human natural killer cells designed to penetrate tumors and induce apoptosis in cancer cells; intended for intravenous infusion in clinical settings.
Services
Partnerships with clinical sites, researchers, and industry to perform preclinical studies and plan future clinical trials for EV-based therapies.
Partnerships with clinical sites, researchers, and industry to perform preclinical studies and plan future clinical trials for EV-based therapies.
Expertise Areas
- Extracellular vesicle therapeutics
- Immuno-oncology
- Preclinical cancer models and testing
- Biologic formulation and stability
Key Technologies
- Extracellular vesicles (EVs)
- Natural killer (NK) cell biology
- AI/ML imaging for oncology
- Intravenous infusion delivery
News & Updates
Peer-reviewed article reporting that extracellular vesicles derived from the NK3.3 human NK cell line penetrate and selectively kill treatment-resistant tumor cells.
Study describing NK3.3-derived extracellular vesicles as a potential therapeutic approach for multiple myeloma.
Article reporting broad anti-tumor activity of NK3.3-derived extracellular vesicles.
Peer-reviewed article reporting that extracellular vesicles derived from the NK3.3 human NK cell line penetrate and selectively kill treatment-resistant tumor cells.
Study describing NK3.3-derived extracellular vesicles as a potential therapeutic approach for multiple myeloma.
Article reporting broad anti-tumor activity of NK3.3-derived extracellular vesicles.